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OBJECTIVE—Pertussis toxin uncoupling–based studies have
shown that Gi and Go can inhibit insulin secretion in pancre-
atic -cells. Yet it is unclear whether Gi and Go operate
through identical mechanisms and how these G-protein–medi-
ated signals inhibit insulin secretion in vivo. Our objective is to
examine whether/how Go regulates islet development and
insulin secretion in -cells.
RESEARCH DESIGN AND METHODS—Immunoassays were
used to analyze the Go expression in mouse pancreatic cells.
Go was speciﬁcally inactivated in pancreatic progenitor cells by
pancreatic cell–speciﬁc gene deletion. Hormone expression and
insulin secretion in response to different stimuli were assayed in
vivo and in vitro. Electron microscope and total internal reﬂec-
tion ﬂuorescence–based assays were used to evaluate how Go
regulates insulin vesicle docking and secretion in response to
glucose stimulation.
RESULTS—Islet cells differentiate properly in Go
/ mutant
mice. Go inactivation signiﬁcantly enhances insulin secretion
both in vivo and in isolation. Go nullizygous -cells contain an
increased number of insulin granules docked on the cell plasma
membrane, although the total number of vesicles per -cell
remains unchanged.
CONCLUSIONS—Go is not required for endocrine islet cell
differentiation, but it regulates the number of insulin vesicles
docked on the -cell membrane. Diabetes 59:2522–2529, 2010
N
utritional signals, including glucose and amino
acids, are the major inducers for insulin secre-
tion in pancreatic -cells. Upon glucose entry
into -cells, glucokinase initiates glucose me-
tabolism to increase the cytosolic ATP/ADP ratio (1).
Increase in the ATP/ADP ratio leads to closure of KATP
channels and membrane depolarization, which in turn
opens voltage-gated calcium channels and causes in-
creases of intracellular calcium, triggering insulin secre-
tion (2). Neuronal and hormonal signals modulate
secretion in response to nutrients by modifying the activity
and effects of secondary messengers or effector molecules
that control secretion (3–5).
Heterotrimeric G-protein (G) coupled receptors are
the major mediators of hormonal and neuronal signals in
modulating insulin secretion (6,7). Neurotransmitters or
neuropeptides bind their respective receptors to activate
the G-proteins, which subsequently transmit regulatory
signals by modifying the production of secondary messen-
gers or interacting with effector molecules. All G-protein
subunits can transmit signals (8), with G being the major
determinant of the speciﬁcity and strength of signaling
(8,9). There are four subfamilies of G proteins (Gs,
Gq/11, G12/13, and Gi/o). All of these subfamily mem-
bers are expressed in -cells and are thought to be
involved in insulin secretion regulation. For example,
cholecystokinin, glucagon, glucagon-like peptide-1, and
PACAP activate Gs to stimulate adenosine cAMP produc-
tion and potentiate insulin secretion through protein ki-
nase A–dependent and –independent (i.e., cAMP-GEFII)
pathways. In contrast, galanin, somatostatin, and adrena-
line activate Gi/o proteins to inhibit insulin secretion
through both calcium-dependent and -independent pro-
cesses (10). The presence of these different mechanisms
highlights the diverse roles and functions of G-proteins in
regulating insulin secretion.
The collective roles of Gi/o proteins in insulin secre-
tion have long been established. Pertussis toxin (or islet-
activating protein, [PTX]) ADP-ribosylates Gi/o proteins
to release the inhibitory effect of adrenaline on insulin
secretion through Gi/o-coupled receptors (11–13). How-
ever, because PTX modiﬁes Gi1, Gi2, Gi3, and Go
simultaneously, the individual in vivo function of each of
these G-proteins is not clear; whether they function
through a common mechanism is also unclear (14).
Go, the most abundant G-protein in neuronal and
neuroendocrine cells, produces two protein isoforms:
Go1 and Go2, through two alternatively spliced mRNAs
(15,16). The in vivo inhibitory mechanism of Goo n
insulin secretion remains largely unclear due to the possi-
ble redundancy among the Gi/o proteins as well as a lack
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nism is that Go regulates vesicle docking or the vesicle/
cytoplasmic membrane fusion process. This above
hypothesis is in line with some recent ﬁndings that show
the G complex can directly interact with the SNARE
complex in neuroendocrine cells (17–19) to modulate
secretion. Whether Go inhibits insulin secretion through
such a mechanism (e.g., Go regulates the intracellular
G concentration by sequestration in response to hor-
mone stimulation) has not been investigated as of yet.
Go
/ null mice displayed severe physiological defects
such as compromised viability, shortened life span, re-
duced body weight, defects in pain perception, and defects
in movement (tremors and seizures) (20,21). Thus, char-
acterization of their islet phenotype was hindered by these
pleiotropic defects. Here, we used tissue-speciﬁc loss of
function in the mouse to analyze the function of Go
speciﬁcally in islet cells. We show that Go-deﬁcient
-cells have a signiﬁcant increase in cell membrane–
docked insulin vesicles as compared with control cells.
These ﬁndings suggest that Go functions as a repressor
of insulin secretion by delaying the vesicle docking/prim-
ing process, either directly or indirectly, in -cells.
RESEARCH DESIGN AND METHODS
The Pdx1
Cre allele was described previously (22). The derivation of Go
F will
be described elsewhere (M.J., L.B., unpublished data).
Immunoﬂuorescence/immunohistochemistry and RT-PCR followed estab-
lished protocols. Mouse anti-Go was a gift from R. Jahn (23). Guinea pig
anti-insulin, guinea pig anti-glucagon, guinea pig anti-pancreatic polypeptide,
and rabbit anti-somatostatin were obtained from Dako, Carpinteria, CA.
Mouse monoclonal anti-insulin antibody was purchased from Sigma-Aldrich,
St. Louis, MO. Secondary antibodies used were ﬂuorescein isothiocyanate–
conjugated donkey anti-rabbit IgG; ﬂuorescein isothiocyanate–conjugated
donkey anti-guinea pig IgG; and Cy3-conjugated donkey anti-mouse IgG
(Jackson Immunoresearch, West Grove, PA). Goat anti-mouse IgG conjugated
to Alexa Fluor 488 was from Invitrogen, Carlsbad, CA. All antibodies were
used at a 1:500–1:2,000 dilution. Oligos used for Go RT-PCR are as follows
(Fig. 2): P1, 5-cactgagcaggacatcctccga-3; P2, 5-catcctcaaagcagtggatcca-3;
P3, 5-cttcctcaacaagaaagacctct-3; P4, 5-ggtgagcggtttttgctttcaaa-3; P5, 5-ca
agtggttcacagacacatcta-3; P6, 5-ccttggatgtgagccacagct-3. Oligos used for in-
sulin expression assays are as follows: 5-cagcaagcaggtcattgttt-3 and
5-gggaccacaaagatgctgtt-3.
For -cell mass assay, pancreata were weighed and cut as 20-m frozen
sections. One-tenth of the sections were randomly collected and stained for
insulin expression. Confocal images (covering 1/5 of all stained pancreatic
areas) were randomly captured using a 5 objective lens and analyzed with
Bioquant software (24) to calculate the area ratio between -cells and the
whole pancreas to calculate islet mass.
Intraperitoneal PTX injection (at 1 g/100 g body wt), intraperitoneal
glucose tolerance test (IPGTT), insulin sensitivity assays, and serum insulin
assays followed published procedures (25,26). Islet isolation and perifusion
followed an established protocol (27). For cAMP assays, 12 animals of each
genotype were used to prepare eight independent batches of islets. Islets were
incubated in Ringer’s solution (with 2 mmol/l glucose) with 0.1 mmol/l
isobutylmethylxanthine (IBMX) for 2 h and then used for assaying cAMP
levels with the cAMP Biotrak enzyme immunoassay system (GE Healthcare).
For perifusion, islets of similar size and shape were used. Hand-picked islet
cells were isolated and placed in a 1-ml perifusion chamber, equilibrated in 5.6
mmol/l glucose for 30 min and then challenged with 16.7 mmol/l glucose (16.7
mmol/l glucose 	 100 mol/l IBMX), 300 mol/l tolbutamide, and 20 mmol/l
KCl. The perifusion fractions were collected in 3-min intervals at 1 ml/min ﬂow
rate and assayed for insulin by radioimmunoassay.
Fluorescent images were obtained using confocal microscopy (Zeiss LSM
510 inverted microscope). For transmission electron microscopy (TEM), islets
were ﬁrst isolated from six animals and ﬁxed (0.25% gluteraldehyde in PBS)
for sectioning and imaging. For quantiﬁcation of vesicles docked on the cell
membrane, images were captured using TEM at magniﬁcation 10,000–
15,000. The number of docked vesicles was counted before genotype identi-
ﬁcation, with vesicles whose outer surface was within 10 nm of the plasma
membrane as docked granules. At least 50 randomly captured microscopic
ﬁelds (from different -cells) of each genotype were analyzed before identi-
fying their genotype. For calcium imaging, a series of images were acquired
from isolated islets under glucose levels of 2, 4, 6, 8, 10, and 15 mmol/l. Images
were background subtracted, and the mean Fluo-4/Fura-Red intensity ratio
was calculated across the whole islet (28). This ratio was then normalized to
the ratio calculated at 4 mmol/l glucose stimulation.
Total internal reﬂection ﬂuorescence microscopy (TIRFM)-based live cell
imaging followed published procedures (29,30). Brieﬂy, islets were isolated
and dispersed in calcium-free Krebs-Ringer buffer (KRB) containing 1 mmol/l
EGTA and cultured on high refractive index cover glass (Olympus) in RPMI
medium. -Cells were then infected with recombinant adenovirus Adex1CA
insulin-green ﬂuorescent protein (GFP) (29) for observation in KRB contain-
ing 2.2 mmol/l glucose (37°C). The Olympus TIRFM system was used with a
high-aperture objective lens to observe the ﬂuorescence of GFP with a
charge-coupled device camera at 300-ms intervals using Metamorph version
7.1 (Universal Imaging). Stimulation with glucose was achieved by the
addition of 52 mmol/l glucose–KRB into the chamber for a ﬁnal concentration
of 22 mmol/l glucose. Diiodomethane sulfur immersion oil (n 
 1.81, Cargille
Laboratories) was used to make contact between the objective lens and the
high refractive index cover glass. Light propagates through the cover glass at
an angle of 65° and undergoes total internal reﬂection at the glass–cell
interface. The refractive indexes for the glass (n 
 1.8 at 488 nm) and cells
(n 
 1.37) predict an evanescent ﬁeld decline of threefold within 44 nm from
the interface and of 10-fold within 100 nm. Most analyses, including tracking
(single projection of different images) and area calculations were performed
using Metamorph software, added with manual event selection. In this
evanescent ﬁeld setting, a granule would have a vertical distance of 9.6 nm
from the plasma membrane and qualify as a morphologically docked granule
(granule distance from plasma membrane 10 nm in electron microscopic
studies) (31). We immunostained endogenous insulin granules in ﬁxed pan-
creatic -cells. Then, we manually counted bright spots as the docked
granules.
All statistical analyses used the Student t test. A P value  0.05 was
considered statistically signiﬁcant. Quantiﬁed data are presented as mean  SE.
RESULTS
Go is expressed in all endocrine islet cells. We
examined Go protein expression in both embryonic and
adult pancreata using a monoclonal antibody that recog-
nized both Go1 and Go2. Robust Go production is
detected in all hormone-expressing cells in all stages
examined, including E11.5, E17.5, and 3-month-old adults
(Fig. 1). We do not detect Go in exocrine acinar or
pancreatic duct cells (Fig. 1 and data not shown). Further
RT-PCR analyses showed that both Go1 and Go2 mRNA
could be detected in adult islet cells, suggesting that both
isoforms might be involved in islet cell function (Fig. 2A
and B).
Go is not required for endocrine islet cell differen-
tiation. We used a Go conditional allele, in which two
LoxP sites ﬂanked the ﬁfth and sixth exons of Go,
common to Go1 and Go2 (Go
F, Fig. 2A), to examine its
role in -cell function. Deletion of the ﬂanked exons
produces a truncated mRNA that only codes for the
NH2-terminal 156 amino acids, which lacks all motifs that
bind to adenylyl cyclase, phospholipase Cs (PLCs), and the
 subunits. We expect that this above manipulation
results in a null Go allele (Go
). Indeed, Go
/ ani-
mals display identical phenotypes as previously reported
for null mutants (data not shown), whereas Go
	/ mice
showed a similar phenotype as wild-type littermates. Fur-
thermore, the truncated protein did not perturb insulin
secretion in a cultured -cell line (supplementary Fig. 1,
available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db09-1719/DC1).
Go
F/F;Pdx1
Cre (F/F;Cre) adult animals were derived
from standard genetic crosses. Pdx1
Cre animals express
Cre in all undifferentiated pancreatic progenitors and
inactivate Go in all pancreatic progenitor cells of F/F;Cre
mice. This allows us to examine whether Go plays a role
in islet cell development. In addition, no Cre toxicity in
A. ZHAO AND ASSOCIATES
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Cre animals has been observed (22). RT-PCR assays
showed that the mRNA sequence corresponding to the
ﬁfth and sixth exons of Go was no longer detectable in
islets of 4-month-old F/F;Cre animals (Fig. 2B), conﬁrming
the effectiveness of Pdx1
Cre for Go
F deletion.
The F/F;Cre animals were no different in body weight
from their control littermates (Go
F/F or F/F) at all ages
examined: 6, 9, 12, and 20 weeks (Fig. 2C). Additionally, no
structural or behavioral (aggression, feeding, moving, and
mating) defects were obvious in these animals. At postna-
tal day 1 (P1), the insulin contents in F/F;Cre and F/F
pancreata were not signiﬁcantly different (supplementary
Fig. 2A, available in an online appendix), suggesting that
Go is not required for -cell differentiation. By P28, the
insulin content in F/F;Cre animals was reduced by 20%
over that of control littermates (Fig. 2D). At P56 (8 weeks),
the insulin content of F/F;Cre animals had a 38% reduction
compared with control littermates (Fig. 2D). Consistent
with this ﬁnding, the -cell mass was reduced in F/F;Cre
animals at P56 as well (Fig. 2E–G). The reason for this
reduction in insulin content is not currently clear.
We analyzed islet morphology and expression of several
genes that are required for endocrine islet cell differenti-
ation and function, including MafA, MafB, Myt1, Nkx6.1,
and Pdx1 (25) by immunoﬂuorescence. None of the above
markers were affected by Go inactivation (supplemen-
tary Fig. 2B and data not shown). These data suggest that
Go is not required for islet neogenesis, even though it is
expressed in early Ngn3-expressing endocrine progenitor
cells (32).
Go is the major mediator of PTX’s effect on insulin
secretion inhibition. Gi and Go inactivation by PTX
uncouples the inhibitory effects of some neural hormones,
such as adrenaline, on insulin secretion (12). Because both
Gi and Go are expressed in islet cells and they both can
be ADP-ribosylated by PTX (14,33,34), it is not clear which
G-protein is mediating the PTX effect on insulin secretion.
We used the Go mutant allele to directly investigate this
question.
The fasting blood glucose levels in F/F;Cre and F/F
animals were similar (Fig. 3A, note the data points at 0
min). However, IPGTT showed that F/F;Cre animals have
signiﬁcantly improved glucose clearance over control lit-
termates (Fig. 3A). Consistent with this observation, the
fasting serum insulin levels are similar between F/F and
F/F;Cre animals. Fifteen minutes after glucose challenge,
the serum insulin levels in F/F control animals increased
by 2-fold but increased up to 10-fold in F/F;Cre mice (Fig.
3B). Because the insulin sensitivity in F/F;Cre and control
animals was similar (Fig. 3C), the above ﬁndings demon-
strate that losing Go potentiates insulin secretion from
-cells. We next tested whether Gi proteins function to
repress insulin secretion in the absence of Go. If they do,
we expect that PTX treatment of F/F;Cre animals would
further potentiate insulin secretion. PTX injection into F/F
animals resulted in a signiﬁcant increase in glucose toler-
ance. Whereas PTX injection into F/F;Cre animals had no
signiﬁcant effect (Fig. 3D), suggesting that although Gi
proteins are expressed in islet cells and may be ADP-
ribosylated by PTX, Go is the major mediator of PTX’s
effect on insulin secretion.
Go regulates insulin secretion at steps shared by
different secretagogues. Islet perifusion assays were
used to directly test how Go inactivation affects insulin
secretion in vitro. Islets from 2-month-old animals were
assayed for insulin secretion in response to glucose, IBMX,
tolbutamide, and KCl stimulation. Glucose induces insulin
secretion through metabolism to alter the ATP/ADP ratio
and other metabolites. IBMX inhibits cAMP phosphodies-
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FIG. 1. Go is expressed in the endocrine islet cells of the pancreas.
Expression patterns at three mouse stages, E11.5 (A), E17.5 (B–E),
and 3-month-old adult (F–I), are shown. Immunoﬂuorescence was used
to visualize coexpression of Go with each endocrine hormone. Three
panels: Go, hormone (green), and a merged image. Note that all
hormone-expressing cells express Go. Scale bar  20 m. PP, pancre-
atic polypeptide; SS, somatostatin. (A high-quality digital representa-
tion of this ﬁgure is available in the online issue.)
FIG. 2. Go is not required for islet cell differentiation. A: A diagram
showing the Go
F (F) allele. Only some exons are shown (from 5 to 8).
Exons 7 and 8 are speciﬁc to Go2. Exons 7 and 8 are speciﬁc to
Go1. Arrows P1–P6 indicate the oligonucleotides used for detecting
Go mRNAs in B, which shows RT-PCR detection of Go mRNA in
4-month-old adult islet cells. RT reactions with insulin-speciﬁc oligos
were used as controls (with or without reverse transcription). (P5 
P6) detects Go1 mRNA. (P3  P4) detects Go2 mRNA (Cre refers to
Go
F/F; Pdx1
Cre). (P1  P2) detects both Go1 and Go2 messages. C:
Body weights of F/F and F/F;Cre animals at 12 weeks of age. D: Total
insulin content in 4- and 8-week-old mice (P28 and P56). E and F:
Insulin staining (red) in P56 pancreata. Topro3 (blue) highlights all
pancreatic tissues. Scale bar  50 m. G: -Cell mass in P56 animals.
*P < 0.05. (A high-quality color representation of this ﬁgure is
available in the online issue.)
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protein kinase A and/or GEFII to facilitate insulin vesicle
exocytosis (35,36). Tolbutamide, a KATP channel blocker,
depolarizes -cell membrane potential, as does KCl. In
response to these stimuli, the insulin secretion in the
F/F;Cre islets was substantially increased compared with
that of control littermates at every time point examined
(Fig. 4A). The biggest increase was in response to glucose,
increasing as much as 369% (Fig. 4B). This secretion
increase was lower than what was detected during in vivo
glucose challenge (Fig. 3B), likely due to the synergetic
effect of multiple hormones that regulate insulin secretion
through Go in vivo, but not in vitro. Importantly, these
data suggest that Go regulates insulin secretion through
a mechanism that is shared by all these stimuli, most likely
in steps that are distal to Ca
2	 mobilization, as suggested
for in vitro–based studies (10).
Indeed, inactivation of Go did not signiﬁcantly affect
cAMP production in isolated islets (Fig. 4C). In addition,
similar increases in intracellular free calcium ([Ca
2	]i)
concentration were seen in both F/F;Cre mutant and
control islets after elevated glucose stimulation (Fig. 5).
Synchronous bursting and spiking activities were ob-
served at 8, 10, and 15 mmol/l glucose, respectively (Fig.
5A and data not shown), in both sets of islets. The mean
fold increase in [Ca
2	]i was also similar for various levels
of glucose stimulation for both mutant and wild-type islets
(Fig. 5B). This result suggests that Go has little effect on
-cell electrical activity and suggests that Go regulates
insulin secretion downstream of elevated [Ca
2	]i in vivo.
Go inhibits insulin granule docking to the -cell
plasma membrane. We next examined how Go affects
insulin secretion. Because insulin vesicle docking on the
cell membrane is necessary for insulin secretion, we used
TEM to investigate whether vesicle distribution in -cells
is affected by loss of Go. The size of each vesicle in
-cells did not vary between F/F;Cre and F/F control islets
(Fig. 6A and B). The density of granules in the F/F;Cre and
control -cell remained unchanged as well (Fig. 6E).
However, the number of secretory vesicles in direct con-
tact with the cell membrane increased by about 100% in
F/F;Cre -cells as compared with that of controls (Fig. 6C,
D, and F). Because TEM only allows us to examine vesicle
docking on a thin section with limited depth, we used
TIRFM to verify the above ﬁndings. TIRFM uses evanes-
cent light waves to selectively illuminate the -cell surface
at a 100-nm depth. Thus, this technique allows us to
exclusively visualize the granules that localize in the
proximity of the cell membrane on a wide cell surface
area. Isolated islet cells were ﬁxed and stained with insulin
antibodies and subjected to TIRFM (Fig. 6G). Consistent
with the above TEM-based ﬁnding, we observed a signiﬁ-
cant (P  0.01) increase in the number of insulin vesicles
close to plasma membrane in Go mutants (257/m
2) over
that of the control cells (190/m
2) (Fig. 6F). Note that the
fold increase of docked vesicles revealed by TIRFM (a 35%
increase) is lower than that observed from TEM-based
analysis (100% increase). This is an expected result be-
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FIG. 3. Pancreas-speciﬁc Go inactivation enhances glucose-clearing
capability in adult animals. A: IPGTT results in 6- and 12-week-old
animals. Go
F/F;Pdx1
Cre (F/F;Cre) and Go
F/F (F/F) animals were used.
At least 13 males and 13 females of each genotype were assayed.
Presented are the combined results from both males and females. B:
Serum insulin levels 0 and 15 min after intraperitoneal glucose injec-
tion in 12-week-old F/F;Cre and F/F males. Note the fold increases in
both control (gray bars) and F/F;Cre (black bars) animals after glucose
stimulation. C: Insulin sensitivity of 12-week-old F/F;Cre and F/F
animals. The y-axis is presented as the ratio of glucose levels of the
assay point over that of the 0-min value. D: IPGTT results in animals
treated with PTX. *P < 0.01.
FIG. 4. Go nullizygous islets secrete more insulin in response to
multiple stimulations. A: Perifusion assay results. Note the enhanced
insulin secretion response to different secretagogues. IEQ  islet
equivalent. *P < 0.01. B: Total insulin release induced by different
secretagogues. Data are integrated from A. C: cAMP levels in mutant
and control islets. The cAMP concentration is normalized against the
OD280 of islet extract (as an assay of protein content).
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plasma membrane, which is only a small portion of the
vesicles that localize within 100 nm of the plasma mem-
brane visualized through TIRFM. Additionally, our vesicle
density count with EM and TIRFM displayed a twofold
difference (Fig. 6E and H). This discrepancy could be due
to the unequal vesicle distribution within the cytoplasmic
compartment and cell membrane. Alternatively, it is pos-
sible that TIRFM only visualizes high-insulin-content ves-
icles (due to antibody staining–related issues), whereas
EM allows us to visualize all vesicles.
Go inactivation expedites vesicle release in -cells
but does not affect vesicle trafﬁcking from cytoplasm
to plasma membrane. TIRFM visualizes vesicle move-
ment in vivo in real time. We therefore recorded the
vesicular dynamics close to the -cell membrane in wild-
type and Go mutant animals. Dissociated -cells were
transfected with retroviral particles that expressed a hu-
man insulin–enhanced green ﬂuorescent protein (EGFP)
fusion protein, which was previously shown to be pack-
aged in normal insulin vesicles and to not interfere with
insulin trafﬁcking. As a result, the EGFP-marked insulin
vesicles could be followed in real time (29,37).
Islet cells were stimulated with 22 mmol/l glucose (see
RESEARCH DESIGN AND METHODS). Vesicular movements close
to the -cell membrane were recorded at 300-ms intervals
with TIRFM. The number of fusion events at the plasma
membrane was counted at 1-min intervals. Consistent with
the perifusion assays (Fig. 4), Go mutant -cells release
signiﬁcantly more vesicles than control -cells (Fig. 7A). In
this regard, it is possible that Go inactivation could either
shorten vesicle residence time on the plasma membrane
before fusion or expedite transportation of vesicles from
cytoplasm to plasma membrane. In order to differentiate
between these possibilities, we counted the fusion events
from predocked vesicles and newly arrived vesicles (new-
comers or vesicles that appear close to cell membranes
after the start of recording) during stimulation. Membrane-
docked vesicles in Go mutant -cells showed a trend of
increased readiness for release (Fig. 7B). Speciﬁcally,
upon glucose stimulation, 23.1% of predocked insulin
vesicles were released within 10 min in control -cells,
whereas 35.7% of predocked vesicles were released within
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FIG. 5. Calcium responses were not altered in Go mutant islets. A:
Representative time courses of [Ca
2]i activity estimated from the
normalized Fluo4/FuraRed intensity ratio in both F/F (left) and F/F;
Cre islets (right) 10 min after glucose challenge. Shown are data from
representative islets. Each islet was monitored continuously for 2 min.
Note that 2 mmol/l glucose does not elicit Ca
2 mobilization, whereas
8 mmol/l glucose induces synchronous bursting of Ca
2 activity in both
sets of islets; 15 mmol/l glucose induces continuous spiking in both sets
of islets. B: Fold increases in [Ca
2]i estimated from the normalized
Fluo4/FuraRed intensity ratio for control islets (black) and mutant
islets (gray) under varying glucose stimulation. All data are normal-
ized to Fluo4/FuraRed intensity ratio at 4 mmol/l glucose.
FIG. 6. Go inactivation increases insulin vesicle docking to -cell
membrane. A–D: TEM images highlighting insulin vesicle density (A
and B). Note that different -cells have different vesicle density or
membrane-associated vesicles (C and D). Arrows, membrane-docked
vesicles. E: Vesicle density in -cells, presented as number of vesicles
on two-dimensional views. F: Number of vesicles docked onto cytoplas-
mic membrane from EM-based analysis. Data are presented as number
of vesicles over length of intercellular junctions (P < 0.01). G: TIRFM
images showing the presence of insulin vesicles on the surface of ﬁxed
and insulin Ab-stained -cells of control (F/F) and Go deleted (F/F;
Cre) animals. Vesicles within the circled areas were counted and
presented in H.
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represents a 52% increase. On the contrary, the fusion
events contributed by newly arrived vesicles did not
display a signiﬁcant difference between the control and
mutant -cells (Fig. 7C, 174  58 vs. 213  68; 23%
difference). Overall, these data suggest that one of the
possible Go functions is to facilitate vesicle docking and,
to a lesser extent, to increase the readiness of vesicle
fusion to the plasma membrane (Fig. 7D).
DISCUSSION
Although the role of Go in insulin secretion has been
implicated for one-half century from PTX-based G-protein
uncoupling studies (11–13), the nonspeciﬁcity of PTX
(which inactivates both Gi and Go) has made it impos-
sible to investigate how Go functions in vivo. Our ﬁnd-
ings suggest that Go might regulate insulin granule
dynamics distal to Ca
2	 mobilization in vivo, a conclusion
drawn from cell culture–based studies (38–42).
Vesicle docking is an essential step for insulin secretion.
Each -cell contains more than 10,000 vesicles (43,44), yet
only a small portion of these vesicles can be readily
released within the ﬁrst phase of glucose induction (10
min in all studied species) (2,7). Subsequently, insulin
vesicles are transported from cytoplasm to the plasma
membrane for docking, priming, and fusion to sustain the
second phase of release. Thus, vesicle docking, although
not the rate-limiting step for insulin secretion, likely plays
an essential role in regulating insulin secretion. Consistent
with this hypothesis, adult -cells that have lost the
transcription factor gene FoxA2 have more insulin vesicles
docked on the cell membrane, and this phenotype is
accompanied by excessive glucose-stimulated insulin se-
cretion (45). Thus, understanding vesicle trafﬁcking could
provide key insights into the mechanisms that regulate
insulin release in response to nutritional, neuronal, and
hormonal stimuli.
Both our TEM- and TIRFM-based studies show that loss
of Go results in more vesicles docking to the plasma
membrane at the resting state. Furthermore, the docked
vesicles in Go nullizygous -cells appear more likely to
fuse with the plasma membrane than docked vesicles in
control cells. These data, combined with the ﬁnding that
Go inactivation does not signiﬁcantly alter the transport
of vesicles to plasma membrane, suggest that Go could
delay vesicle docking and possibly repress vesicle priming.
Further supporting this notion is our ﬁnding that Go does
not appear to affect calcium ﬂux, which seems to contra-
dict some previously published ﬁndings (10). It is likely
that only speciﬁc G-protein (G)-coupled receptor–
ligand coupling could affect channel activity via Go,
which cannot be activated in our in vitro assay. Alterna-
tively, the in vitro assays may not be sensitive enough to
detect the subtle channel activity alteration with or with-
out Go. For example, Go could regulate the resting
Ca
2	 levels in -cells, which would be consistent with the
ﬁnding that resting Ca
2	 level affects the pool size of
readily releasable granules (46). It would be interesting to
analyze whether hormones, such as galanin, somatostatin,
or adrenaline, can regulate speciﬁc channel activities in
the presence or absence of Go and how this might affect
the resting Ca
2	 levels in isolated islets.
How Go modulates the vesicle docking/priming pro-
cess is not known. Because there are high levels of Go
protein in neuronal and neuroendocrine cells, it was
proposed that one function of Go was to act as a
reservoir for the G subunits within cells. When stimu-
lated, Go will dissociate from the G to release G as
an effector to regulate cell function. Several lines of
existing evidence support this possibility. First, expressing
aG  binding protein, the PH domain of the G-protein–
linked receptor kinase 2 stimulates insulin secretion in
response to secretagogues, similar to the consequences of
G trimer formation (47). Second, introducing G
proteins in neuronal cells mimics the effect of Go protein
activation, that is, dissociation of the G complex (48).
In line with this possibility, loss of Go could reduce
cellular G subunits, which results in dysregulated vesi-
cle trafﬁcking and secretion (17). Unfortunately, it is
currently unknown which speciﬁc -o r-subunit interacts
with Go and has thus prevented us from directly exam-
ining this possibility. Alternatively, Go proteins could
directly interact with unknown effectors to regulate insu-
lin secretion. Solving this issue will likely require a com-
prehensive understanding of all the protein/effectors that
speciﬁcally interact with Go under normal physiological
conditions. We currently do not know which possibility is
likely to occur.
In summary, our analysis suggests that Go modulates
insulin secretion by regulating vesicle docking on the
-cell membrane. Addressing the speciﬁc mechanism
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FIG. 7. Go
/ cells release insulin vesicles more readily upon glucose
stimulation. A: The numbers of vesicle–plasma membrane fusion events
at several time points with 22 mmol/l glucose stimulation. The events
are presented as fusions from predocked vesicles and fusions from
newly arrived vesicles, respectively. B: The percent of predocked
vesicles that are released within 10 min of glucose stimulation. C: The
number of newly arrived vesicles that are released within 10 min of
glucose induction. D: A simple model summarizing where Go could
exert its function in the vesicle-secretion process, including vesicle
docking and possibly priming.
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interact with Go and how these proteins modulate vesi-
cle trafﬁcking, docking, priming, and fusion processes.
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